Anti‐SARS‐CoV‐2 spike immunoglobulin G and immunoglobulin M titers decline as interval from the second inactivated vaccine dose to the onset of illness is prolonged in breakthrough infection patients
Abstract Background Understanding of the early immune response in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) breakthrough infections is limited. Methods Ninety‐eight patients with coronavirus disease 2019 (COVID‐19) breakthrough infections were divided into two groups, with interva...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-04-01
|
| Series: | The Clinical Respiratory Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/crj.13590 |
| _version_ | 1797844327412531200 |
|---|---|
| author | Chuan‐cai Xu Zhi‐song He Wei Lei Jin‐zhou Zhu Da‐guo Zhao Jin‐dan Kong Yao Wei Ying Xu Jian‐An Huang |
| author_facet | Chuan‐cai Xu Zhi‐song He Wei Lei Jin‐zhou Zhu Da‐guo Zhao Jin‐dan Kong Yao Wei Ying Xu Jian‐An Huang |
| author_sort | Chuan‐cai Xu |
| collection | DOAJ |
| description | Abstract Background Understanding of the early immune response in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) breakthrough infections is limited. Methods Ninety‐eight patients with coronavirus disease 2019 (COVID‐19) breakthrough infections were divided into two groups, with intervals from receiving the second dose of inactivated vaccine to the onset of illness <60 or ≥60 days. Results The median lymphocyte count and the median anti‐SARS‐CoV‐2 spike immunoglobulin G (IgG) and immunoglobulin M (IgM) titers were higher in the <60‐day interval group compared with the corresponding medians in the ≥60‐day interval group (p = 0.005, p = 0.001, and p = 0.001, respectively). The median interleukin‐6 (IL‐6) level in the <60‐day interval group was significantly lower than the median IL‐6 level in the ≥60‐day interval group (p < 0.001). Conclusions Our results highlight the different anti‐SARS‐CoV‐2 spike IgG and IgM antibody titers among patients with different intervals from receiving the second dose of inactivated vaccine to the onset of illness. |
| first_indexed | 2024-04-09T17:20:30Z |
| format | Article |
| id | doaj.art-691222a8326f448584eb98b4bdd3772a |
| institution | Directory Open Access Journal |
| issn | 1752-6981 1752-699X |
| language | English |
| last_indexed | 2024-04-09T17:20:30Z |
| publishDate | 2023-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Clinical Respiratory Journal |
| spelling | doaj.art-691222a8326f448584eb98b4bdd3772a2023-04-19T03:06:49ZengWileyThe Clinical Respiratory Journal1752-69811752-699X2023-04-0117427027610.1111/crj.13590Anti‐SARS‐CoV‐2 spike immunoglobulin G and immunoglobulin M titers decline as interval from the second inactivated vaccine dose to the onset of illness is prolonged in breakthrough infection patientsChuan‐cai Xu0Zhi‐song He1Wei Lei2Jin‐zhou Zhu3Da‐guo Zhao4Jin‐dan Kong5Yao Wei6Ying Xu7Jian‐An Huang8Department of Pulmonary and Critical Care Medicine the First Affiliated Hospital of Soochow University Suzhou ChinaDepartment of Cardiology the First Affiliated Hospital of Soochow University Suzhou ChinaDepartment of Pulmonary and Critical Care Medicine the First Affiliated Hospital of Soochow University Suzhou ChinaDepartment of Gastroenterology the First Affiliated Hospital of Soochow University Suzhou ChinaDepartment of Critical Care Medicine the First Affiliated Hospital of Soochow University Suzhou ChinaDepartment of Critical Care Medicine the First Affiliated Hospital of Soochow University Suzhou ChinaDepartment of Critical Care Medicine the First Affiliated Hospital of Soochow University Suzhou ChinaDepartment of Infectious Diseases the First Affiliated Hospital of Soochow University Suzhou ChinaDepartment of Pulmonary and Critical Care Medicine the First Affiliated Hospital of Soochow University Suzhou ChinaAbstract Background Understanding of the early immune response in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) breakthrough infections is limited. Methods Ninety‐eight patients with coronavirus disease 2019 (COVID‐19) breakthrough infections were divided into two groups, with intervals from receiving the second dose of inactivated vaccine to the onset of illness <60 or ≥60 days. Results The median lymphocyte count and the median anti‐SARS‐CoV‐2 spike immunoglobulin G (IgG) and immunoglobulin M (IgM) titers were higher in the <60‐day interval group compared with the corresponding medians in the ≥60‐day interval group (p = 0.005, p = 0.001, and p = 0.001, respectively). The median interleukin‐6 (IL‐6) level in the <60‐day interval group was significantly lower than the median IL‐6 level in the ≥60‐day interval group (p < 0.001). Conclusions Our results highlight the different anti‐SARS‐CoV‐2 spike IgG and IgM antibody titers among patients with different intervals from receiving the second dose of inactivated vaccine to the onset of illness.https://doi.org/10.1111/crj.13590anti‐SARS‐CoV‐2 spike IgG antibodyanti‐SARS‐CoV‐2 spike IgM antibodyIL‐6inactivated vaccinelymphocyteSARS‐CoV‐2 |
| spellingShingle | Chuan‐cai Xu Zhi‐song He Wei Lei Jin‐zhou Zhu Da‐guo Zhao Jin‐dan Kong Yao Wei Ying Xu Jian‐An Huang Anti‐SARS‐CoV‐2 spike immunoglobulin G and immunoglobulin M titers decline as interval from the second inactivated vaccine dose to the onset of illness is prolonged in breakthrough infection patients The Clinical Respiratory Journal anti‐SARS‐CoV‐2 spike IgG antibody anti‐SARS‐CoV‐2 spike IgM antibody IL‐6 inactivated vaccine lymphocyte SARS‐CoV‐2 |
| title | Anti‐SARS‐CoV‐2 spike immunoglobulin G and immunoglobulin M titers decline as interval from the second inactivated vaccine dose to the onset of illness is prolonged in breakthrough infection patients |
| title_full | Anti‐SARS‐CoV‐2 spike immunoglobulin G and immunoglobulin M titers decline as interval from the second inactivated vaccine dose to the onset of illness is prolonged in breakthrough infection patients |
| title_fullStr | Anti‐SARS‐CoV‐2 spike immunoglobulin G and immunoglobulin M titers decline as interval from the second inactivated vaccine dose to the onset of illness is prolonged in breakthrough infection patients |
| title_full_unstemmed | Anti‐SARS‐CoV‐2 spike immunoglobulin G and immunoglobulin M titers decline as interval from the second inactivated vaccine dose to the onset of illness is prolonged in breakthrough infection patients |
| title_short | Anti‐SARS‐CoV‐2 spike immunoglobulin G and immunoglobulin M titers decline as interval from the second inactivated vaccine dose to the onset of illness is prolonged in breakthrough infection patients |
| title_sort | anti sars cov 2 spike immunoglobulin g and immunoglobulin m titers decline as interval from the second inactivated vaccine dose to the onset of illness is prolonged in breakthrough infection patients |
| topic | anti‐SARS‐CoV‐2 spike IgG antibody anti‐SARS‐CoV‐2 spike IgM antibody IL‐6 inactivated vaccine lymphocyte SARS‐CoV‐2 |
| url | https://doi.org/10.1111/crj.13590 |
| work_keys_str_mv | AT chuancaixu antisarscov2spikeimmunoglobulingandimmunoglobulinmtitersdeclineasintervalfromthesecondinactivatedvaccinedosetotheonsetofillnessisprolongedinbreakthroughinfectionpatients AT zhisonghe antisarscov2spikeimmunoglobulingandimmunoglobulinmtitersdeclineasintervalfromthesecondinactivatedvaccinedosetotheonsetofillnessisprolongedinbreakthroughinfectionpatients AT weilei antisarscov2spikeimmunoglobulingandimmunoglobulinmtitersdeclineasintervalfromthesecondinactivatedvaccinedosetotheonsetofillnessisprolongedinbreakthroughinfectionpatients AT jinzhouzhu antisarscov2spikeimmunoglobulingandimmunoglobulinmtitersdeclineasintervalfromthesecondinactivatedvaccinedosetotheonsetofillnessisprolongedinbreakthroughinfectionpatients AT daguozhao antisarscov2spikeimmunoglobulingandimmunoglobulinmtitersdeclineasintervalfromthesecondinactivatedvaccinedosetotheonsetofillnessisprolongedinbreakthroughinfectionpatients AT jindankong antisarscov2spikeimmunoglobulingandimmunoglobulinmtitersdeclineasintervalfromthesecondinactivatedvaccinedosetotheonsetofillnessisprolongedinbreakthroughinfectionpatients AT yaowei antisarscov2spikeimmunoglobulingandimmunoglobulinmtitersdeclineasintervalfromthesecondinactivatedvaccinedosetotheonsetofillnessisprolongedinbreakthroughinfectionpatients AT yingxu antisarscov2spikeimmunoglobulingandimmunoglobulinmtitersdeclineasintervalfromthesecondinactivatedvaccinedosetotheonsetofillnessisprolongedinbreakthroughinfectionpatients AT jiananhuang antisarscov2spikeimmunoglobulingandimmunoglobulinmtitersdeclineasintervalfromthesecondinactivatedvaccinedosetotheonsetofillnessisprolongedinbreakthroughinfectionpatients |